Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Formycon AG (FYB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
40.25 +0.30    +0.75%
07:09:16 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE000A1EWVY8 
WKN:  A1EWVY
  • Volume: 2,600
  • Bid/Ask: 40.20 / 40.45
  • Day's Range: 39.90 - 40.55
Formycon 40.25 +0.30 +0.75%

Formycon AG Company Profile

 
Get an in-depth profile of Formycon AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

224

Equity Type

ORD

Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Contact Information

Address Fraunhoferstrasse 15 Martinsried
Planegg, 82152
Germany
Phone 49 89 864 667 100
Fax 49 89 864 667 110
Web www.formycon.com

Top Executives

Name Age Since Title
Peter Wendeln - 2010 Deputy Chairman of Supervisory Board
Olaf Stiller 45 2010 Chairman of Supervisory Board
Johannes Buchner - 2016 Member of Advisory Board
Gerhard Schaefer - 2013 Member of Advisory Board
Bernhard Hampl 73 2014 Member of Advisory Board
Thomas Siklosi - 2018 Member of Advisory Board
Klaus Rohrig - 2020 Member of Supervisory Board
Wolfgang Essler - 2023 Member of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

FYB Comments

Write your thoughts about Formycon AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lukas Roegler
Lukas Roegler Mar 30, 2022 5:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Next phase initiated.
Reply
1 0
Report
Financial Advisors
Financial Advisors Dec 09, 2021 2:31AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why is up today any special reason ?
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Dec 09, 2021 2:31AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Positive news on their anti-Covid-19 drug today
Reply
1 0
Report
Financial Advisors
Financial Advisors Dec 09, 2021 2:31AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
will jump tommorow tomorrow ?????
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Dec 09, 2021 2:31AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I don't trade. I invest. Buy this and hold until 300 in the next few years.
Reply
0 0
Report
Trading Surfer
TradingSurfer Dec 08, 2021 9:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
up up :-)
Reply
1 0
Report
Gi Mi
Gi Mi Jun 09, 2021 7:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Boom
Reply
2 2
Report
Gi Mi
Gi Mi Feb 26, 2021 9:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I have a friend that works there, it will boom soon
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Feb 26, 2021 9:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It is already booming. Looking forward to more boom. 🚀
Reply
0 0
Report
erdem baskurt
erdem baskurt Jan 04, 2021 9:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is there any news about Nasdaq listing?
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Jan 04, 2021 9:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Is that more than a rumour?
Reply
1 0
Report
erdem baskurt
erdem baskurt Jan 04, 2021 9:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lukas Roegler  no idea :/
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Jan 04, 2021 9:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What I meant to say is that this makes perfect sense for them medium term, but that they need to take a few steps before they could go ahead with a NASDAQ listing. So I think this not more than a rumour FOR NOW.
Reply
1 0
Report
Erik Kraft
Erik Kraft Dec 18, 2020 6:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is really volatile, but good for daytrading, similar to Varta
Reply
2 1
Report
erdem baskurt
erdem baskurt Dec 16, 2020 3:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
but i believe that its gonna be the same like biontech; will pumped again
Reply
2 0
Report
Lukas Roegler
Lukas Roegler Dec 16, 2020 3:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I agree. It could be a similar story eventually including a NASDAQ listing and big investors coming on board.
Reply
1 0
Report
erdem baskurt
erdem baskurt Dec 16, 2020 3:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
big loss now
Reply
1 0
Report
Lukas Roegler
Lukas Roegler Dec 16, 2020 3:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Normal profit taking after such a steep rise
Reply
0 0
Report
Lukas Roegler
Lukas Roegler Dec 11, 2020 1:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone else enjoying the ride?
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email